DE69503753T2 - Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung - Google Patents

Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung

Info

Publication number
DE69503753T2
DE69503753T2 DE69503753T DE69503753T DE69503753T2 DE 69503753 T2 DE69503753 T2 DE 69503753T2 DE 69503753 T DE69503753 T DE 69503753T DE 69503753 T DE69503753 T DE 69503753T DE 69503753 T2 DE69503753 T2 DE 69503753T2
Authority
DE
Germany
Prior art keywords
production
tetracyclic derivatives
tetracyclic
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69503753T
Other languages
English (en)
Other versions
DE69503753D1 (de
Inventor
Alain Claude-Marie Daugan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icos Corp
Original Assignee
Icos Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10749089&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69503753(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Icos Corp filed Critical Icos Corp
Publication of DE69503753D1 publication Critical patent/DE69503753D1/de
Application granted granted Critical
Publication of DE69503753T2 publication Critical patent/DE69503753T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
DE69503753T 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung Expired - Lifetime DE69503753T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB9401090A GB9401090D0 (en) 1994-01-21 1994-01-21 Chemical compounds
PCT/EP1995/000183 WO1995019978A1 (en) 1994-01-21 1995-01-19 Tetracyclic derivatives, process of preparation and use

Publications (2)

Publication Number Publication Date
DE69503753D1 DE69503753D1 (de) 1998-09-03
DE69503753T2 true DE69503753T2 (de) 1999-01-21

Family

ID=10749089

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2003199006 Active DE10399006I2 (de) 1994-01-21 1995-01-19 Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.
DE69503753T Expired - Lifetime DE69503753T2 (de) 1994-01-21 1995-01-19 Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DE2003199006 Active DE10399006I2 (de) 1994-01-21 1995-01-19 Tetracyclische Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung.

Country Status (49)

Country Link
US (5) US5859006A (de)
EP (1) EP0740668B1 (de)
JP (3) JP3808095B2 (de)
KR (1) KR100357411B1 (de)
CN (2) CN1045777C (de)
AP (1) AP556A (de)
AT (1) ATE169018T1 (de)
AU (2) AU689205B2 (de)
BG (1) BG62733B1 (de)
BR (1) BR9506559C8 (de)
CA (1) CA2181377C (de)
CO (1) CO4340684A1 (de)
CZ (1) CZ286566B6 (de)
DE (2) DE10399006I2 (de)
DK (1) DK0740668T3 (de)
EE (1) EE03231B1 (de)
EG (1) EG25852A (de)
ES (1) ES2122543T3 (de)
FI (1) FI113176B (de)
GB (1) GB9401090D0 (de)
HK (1) HK1013286A1 (de)
HR (1) HRP950023B1 (de)
HU (1) HU222494B1 (de)
IL (1) IL112384A (de)
IN (1) IN183942B (de)
IS (1) IS1888B (de)
LU (1) LU91017I2 (de)
LV (1) LV11690B (de)
MA (1) MA23433A1 (de)
MX (1) MX9602904A (de)
MY (1) MY114663A (de)
NL (1) NL300124I2 (de)
NO (2) NO306465B1 (de)
NZ (1) NZ279199A (de)
OA (1) OA10584A (de)
PE (1) PE49495A1 (de)
PL (1) PL179744B1 (de)
RO (1) RO117794B1 (de)
RU (1) RU2142463C1 (de)
SA (1) SA95150475B1 (de)
SG (1) SG49184A1 (de)
SI (1) SI0740668T1 (de)
SK (1) SK280879B6 (de)
SV (1) SV1995000002A (de)
TN (1) TNSN95004A1 (de)
TW (1) TW378210B (de)
UY (1) UY23893A1 (de)
WO (1) WO1995019978A1 (de)
ZA (1) ZA95424B (de)

Families Citing this family (212)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6143746A (en) * 1994-01-21 2000-11-07 Icos Corporation Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use
GB9511220D0 (en) * 1995-06-02 1995-07-26 Glaxo Group Ltd Solid dispersions
US6060477A (en) 1995-06-07 2000-05-09 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl cycloamino pyrimidinone derivatives
US6262059B1 (en) 1995-06-07 2001-07-17 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with quinazoline derivatives
US6200980B1 (en) 1995-06-07 2001-03-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl purinone derivatives
US5874440A (en) 1995-06-07 1999-02-23 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyrimidinone derivatives
US6046216A (en) 1995-06-07 2000-04-04 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl pyridinone derivatives
US6232312B1 (en) 1995-06-07 2001-05-15 Cell Pathways, Inc. Method for treating patient having precancerous lesions with a combination of pyrimidopyrimidine derivatives and esters and amides of substituted indenyl acetic acides
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
GB9514473D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
EA199800907A1 (ru) 1996-05-10 1999-04-29 Айкос Корпорейшн Производные карболина
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
US6331543B1 (en) 1996-11-01 2001-12-18 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use
US6071934A (en) 1997-03-25 2000-06-06 Cell Pathways, Inc. Indenyl hydroxamic acids, (hydroxy) ureas and urethanes for treating patients with precancerous lesions
DE69833254T2 (de) 1997-06-23 2006-11-02 Cellegy Pharmaceuticals, Inc., Brisbane Microdosistherapie von gefässbedingten erscheinungen durch no-donoren
US6403597B1 (en) * 1997-10-28 2002-06-11 Vivus, Inc. Administration of phosphodiesterase inhibitors for the treatment of premature ejaculation
US6410584B1 (en) 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6268372B1 (en) 1998-09-11 2001-07-31 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones
US6326379B1 (en) 1998-09-16 2001-12-04 Bristol-Myers Squibb Co. Fused pyridine inhibitors of cGMP phosphodiesterase
IL132406A0 (en) * 1998-10-21 2001-03-19 Pfizer Prod Inc Treatment of bph with cgmp elevators
US6133271A (en) 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6348032B1 (en) 1998-11-23 2002-02-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with benzimidazole derivatives
US6211220B1 (en) 1998-11-23 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia with amino or pyridylamino cyclobutene derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6420410B1 (en) 1998-11-24 2002-07-16 Cell Pathways, Inc. Method for treating neoplasia by exposure to N,N′-substituted benzimidazol-2-ones
US6358992B1 (en) 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
CA2367138C (en) * 1999-03-24 2010-10-05 Alejandro M. S. Mayer Anti-inflammatory uses of manzamines
HUP0001632A3 (en) * 1999-04-30 2001-12-28 Lilly Icos Llc Wilmington Pharmaceutical compositions comprising selective phosphodiestherase inhibitors
US6451807B1 (en) 1999-04-30 2002-09-17 Lilly Icos, Llc. Methods of treating sexual dysfunction in an individual suffering from a retinal disease, class 1 congestive heart failure, or myocardial infarction using a PDE5 inhibitor
US6943166B1 (en) * 1999-04-30 2005-09-13 Lilly Icos Llc. Compositions comprising phosphodiesterase inhabitors for the treatment of sexual disfunction
US7235625B2 (en) 1999-06-29 2007-06-26 Palatin Technologies, Inc. Multiple agent therapy for sexual dysfunction
US6821975B1 (en) 1999-08-03 2004-11-23 Lilly Icos Llc Beta-carboline drug products
UA72922C2 (uk) 1999-08-03 2005-05-16 Ліллі Айкос Ллк ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ З <font face="Symbol">b</font>-КАРБОЛІНОМ (ВАРІАНТИ) ТА СПОСІБ ЛІКУВАННЯ СЕКСУАЛЬНОЇ ДИСФУНКЦІЇ
CZ20021151A3 (cs) 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
TW200400821A (en) * 1999-11-02 2004-01-16 Pfizer Pharmaceutical composition (II) useful for treating or preventing pulmonary hypertension in a patient
US6562830B1 (en) 1999-11-09 2003-05-13 Cell Pathways, Inc. Method of treating a patient having precancerous lesions with phenyl quinazolinone derivatives
US6376489B1 (en) * 1999-12-23 2002-04-23 Icos Corporation Cyclic AMP-specific phosphodiesterase inhibitors
US20020013327A1 (en) * 2000-04-18 2002-01-31 Lee Andrew G. Compositions and methods for treating female sexual dysfunction
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
UA74826C2 (en) 2000-05-17 2006-02-15 Ortho Mcneil Pharm Inc ?-carboline derivatives as phosphodiesterase inhibitors
UA72611C2 (uk) * 2000-05-17 2005-03-15 Орто-Макнейл Фармацевтикал, Інк. Похідні заміщеного піролопіридинону, корисні як інгібітори фосфодіестерази
EP1289989A2 (de) * 2000-06-07 2003-03-12 Lilly Icos LLC Derivate des 2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]indol-1,4-dions
JP2004501920A (ja) * 2000-06-23 2004-01-22 リリー　アイコス　リミテッド　ライアビリティ　カンパニー 環状ｇｍｐ特異的ホスホジエステラーゼ阻害剤
ES2269401T3 (es) 2000-06-23 2007-04-01 Lilly Icos Llc Derivados de piracino(1'2':1,6)pirido(3,4-b)indol.
DE60112306T2 (de) 2000-06-26 2006-01-12 Lilly Icos Llc, Wilmington Kondensierte pyrazindionderivate als pde5 inhibitore
AU2001278480A1 (en) * 2000-07-24 2002-02-05 Bayer Crop Science Ag Biphenyl carboxamides
EP1305313A1 (de) * 2000-08-02 2003-05-02 Lilly Icos LLC Kondensierte heterocyclische derivate als phosphodiesterase-inhibitoren
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
ES2248399T3 (es) 2000-10-02 2006-03-16 Lilly Icos Llc Derivados de piridoindol condensado.
WO2002028858A2 (en) * 2000-10-02 2002-04-11 Lilly Icos Llc Hexahydropyrazino `1'2' : 1, 6!- pyrido `3, 4-b! indole-1, 4-dione derivatives for the treatment of cardiovascular disorders and erectile disfunction
US6548508B2 (en) 2000-10-20 2003-04-15 Pfizer, Inc. Use of PDE V inhibitors for improved fecundity in mammals
US6828473B2 (en) 2000-11-01 2004-12-07 Pfizer Inc. Modulation of PDE11A activity
EP1211313A3 (de) * 2000-11-01 2003-04-23 Pfizer Limited Modulation der PDE11A-AKtivität
MXPA03003971A (es) * 2000-11-06 2004-02-12 Lilly Icos Llc Derivados de indol como inhibidores de pde5.
JP4216606B2 (ja) * 2001-04-25 2009-01-28 リリー アイコス リミテッド ライアビリティ カンパニー 化学化合物
JP2004536816A (ja) * 2001-06-05 2004-12-09 リリー アイコス リミテッド ライアビリティ カンパニー Ｐｄｅ５阻害剤としてのカルボリン誘導体
DE60219788T2 (de) * 2001-06-05 2008-01-17 Lilly Icos Llc, Wilmington Tetrazyklische verbindungen als pde5-inhibitoren
WO2002098877A1 (en) * 2001-06-05 2002-12-12 Lilly Icos Llc Pyrazino 1',2':1,6 pyrido 3,4-b indole1,4-dione derivatives
US6984641B2 (en) 2001-06-21 2006-01-10 Lilly Icos Llc. Carboline derivatives as PDE5 inhibitors
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
WO2003042216A1 (en) * 2001-11-09 2003-05-22 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
US6686349B2 (en) * 2001-11-14 2004-02-03 Ortho-Mcneil Pharmaceutical, Inc. Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
US7208516B2 (en) 2002-03-20 2007-04-24 Celgene Corporation Methods of the treatment of psoriatic arthritis using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
US7276529B2 (en) 2002-03-20 2007-10-02 Celgene Corporation Methods of the treatment or prevention of exercise-induced asthma using (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
EP1506015A2 (de) * 2002-05-23 2005-02-16 Pfizer Limited Pharmazeutische kombination von pde5-hemmern und ace-hemmern
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
GB0214784D0 (en) * 2002-06-26 2002-08-07 Pfizer Ltd Novel combination
ES2318175T3 (es) * 2002-07-31 2009-05-01 Lilly Icos Llc Reaccion pictet-splenger modificada y productos preparados a partir de la misma.
GB0219961D0 (en) 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
US7323462B2 (en) 2002-12-10 2008-01-29 Pfizer Inc. Morpholine dopamine agonists
KR20050085563A (ko) 2002-12-13 2005-08-29 워너-램버트 캄파니 엘엘씨 하부요로증상을 치료하기 위한 알파-2-델타 리간드
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
NZ542097A (en) 2003-04-29 2008-12-24 Pfizer Ltd 5,7-Diaminopyrazolo[4,3-d]pyrimidines useful in the treatment of hypertension
CA2525946C (en) * 2003-05-22 2013-01-29 Altana Pharma Ag Composition comprising a pde4 inhibitor and a pde5 inhibitor
DK1644021T3 (da) * 2003-06-13 2012-10-29 Ironwood Pharmaceuticals Inc Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
JP4671123B2 (ja) 2003-06-23 2011-04-13 小野薬品工業株式会社 新規三環性複素環化合物
US7291640B2 (en) 2003-09-22 2007-11-06 Pfizer Inc. Substituted triazole derivatives as oxytocin antagonists
US7572799B2 (en) 2003-11-24 2009-08-11 Pfizer Inc Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors
WO2005058280A2 (en) * 2003-12-12 2005-06-30 Myogen, Inc. Enoximone formulations and their use in the treatment of cardiac hypertrophy and heart failure
WO2005068464A2 (en) * 2003-12-15 2005-07-28 Cadila Healthcare Limited Process for preparing tadalafil and its intermediates
US7649002B2 (en) 2004-02-04 2010-01-19 Pfizer Inc (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists
EP1737448A1 (de) * 2004-03-22 2007-01-03 Myogen, Inc. (s)-enoximonsulfoxid und seine verwendung in der behandlung von pde-iii-vermittelten erkrankungen
JP2007530566A (ja) * 2004-03-22 2007-11-01 ミオゲン インコーポレイティッド （ｒ）−エノキシモンスルホキシドおよびｐｄｅ−ｉｉｉ媒介疾患の治療におけるその使用
WO2005097799A1 (en) 2004-04-07 2005-10-20 Pfizer Limited Pyrazolo`4,3-d! pyrimidines
WO2005116030A1 (en) * 2004-05-31 2005-12-08 Matrix Laboratories Ltd A process for the preparation of tadalafil
US20060292213A1 (en) * 2004-06-23 2006-12-28 Myogen, Inc. Enoximone formulations and their use in the treatment of PDE-III mediated diseases
CA2577442A1 (en) 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
WO2006049986A1 (en) * 2004-10-28 2006-05-11 Dr. Reddy's Laboratories Ltd. Polymorphic forms of tadalafil
KR20070072891A (ko) * 2004-11-02 2007-07-06 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 결정형 및 이의 제조 방법
AR051780A1 (es) * 2004-11-29 2007-02-07 Japan Tobacco Inc Compuestos en anillo fusionados que contienen nitrogeno y utilizacion de los mismos
US7964726B2 (en) 2004-12-22 2011-06-21 Ono Pharmaceutical Co., Ltd. Tricyclic compound and use thereof
EP1851222A1 (de) * 2005-02-25 2007-11-07 Teva Pharmaceutical Industries Ltd Verfahren zur synthetisierung von tadalafil
US20070004737A1 (en) * 2005-02-25 2007-01-04 Inbal Ornan Process of purifying tadalafil
KR20070099035A (ko) * 2005-02-25 2007-10-08 테바 파마슈티컬 인더스트리즈 리미티드 입도가 큰 타달라필 및 이의 제조 방법
US20070088012A1 (en) * 2005-04-08 2007-04-19 Woun Seo Method of treating or preventing type-2 diabetes
KR20070110941A (ko) * 2005-04-12 2007-11-20 테바 파마슈티컬 인더스트리즈 리미티드 타달라필 중간체의 제조 방법
CN101163476A (zh) 2005-04-19 2008-04-16 尼科梅德有限责任公司 用于治疗肺动脉高血压的罗氟司特
US8506934B2 (en) 2005-04-29 2013-08-13 Robert I. Henkin Methods for detection of biological substances
DE602006019231D1 (en) 2005-05-12 2011-02-10 Pfizer Wasserfreie kristalline formen von n-ä1,2-ethoxyethyl)-5-(n-ethyl-n-methylaminoü-7-(4-methylpyridin-2-yl-aminoü-1h-pyrazoloä4,3-düpyrimidin-3-carbonylümethansulfonsäureamid
US20070010525A1 (en) * 2005-06-27 2007-01-11 Meyer Jackson Method and compositions for modulating neuropeptide hormone secretion
US7863274B2 (en) * 2005-07-29 2011-01-04 Concert Pharmaceuticals Inc. Deuterium enriched analogues of tadalafil as PDE5 inhibitors
WO2007016361A2 (en) * 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
WO2007014929A1 (en) 2005-08-03 2007-02-08 Boehringer Ingelheim International Gmbh Use of flibanserin in the treatment of obesity
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
EP2258357A3 (de) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenese mit Acetylcholinesterasehemmer
JP2009507925A (ja) * 2005-09-13 2009-02-26 エラン ファーマ インターナショナル リミテッド ナノ粒子タダラフィル製剤
TR201815853T4 (tr) 2005-10-12 2018-11-21 Besins Healthcare Sarl Hipogonadizmin tedavisinde kullanıma yönelik geliştirilmiş testosteron jeli.
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
WO2007048803A1 (en) 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
WO2007100387A2 (en) * 2005-11-03 2007-09-07 Dr. Reddy's Laboratories Ltd. Process for preparing tadalafil
JP2009514969A (ja) 2005-11-09 2009-04-09 コンビナトアールエックス インコーポレーティッド 医学的状態を治療するための方法、組成物、およびキット
US7202229B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
US7201929B1 (en) * 2005-12-30 2007-04-10 Alan James Group, Llc. Aspirin formulation for cardiovascular health
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
AU2007223036A1 (en) * 2006-03-08 2007-09-13 Braincells, Inc. Modulation of neurogenesis by nootropic agents
US20100216734A1 (en) * 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2004644A1 (de) * 2006-03-24 2008-12-24 Glenmark Pharmaceuticals Limited Verfahren zur herstellung von tadalafil
WO2007124045A2 (en) * 2006-04-20 2007-11-01 Ampla Pharmaceuticals, Inc. Piperidine and piperazine compounds for use in the treatment of obesity, eating disorders and sexual dysfunction by potentiation of mc4 receptor activity
US20100009983A1 (en) * 2006-05-09 2010-01-14 Braincells, Inc. 5 ht receptor mediated neurogenesis
EP2021000A2 (de) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenese mittels angiotensin-modulation
JP2009536667A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド ５ｈｔ受容体介在性の神経新生
US20090291958A1 (en) * 2006-06-08 2009-11-26 Auspex Pharmaceuticals, Inc. Substituted PDE5 inhibitors
WO2008000760A1 (en) 2006-06-30 2008-01-03 Boehringer Ingelheim International Gmbh Flibanserin for the treatment of urinary incontinence and related diseases
US20080009502A1 (en) * 2006-07-07 2008-01-10 Access Business Group International Llc Tadalafil solid composites
CA2657346A1 (en) 2006-07-21 2008-01-24 Novartis Ag Formulations for benzimidazolyl pyridyl ethers
EP2054041A2 (de) 2006-08-14 2009-05-06 Boehringer Ingelheim International GmbH Formulierungen von flibanserin und herstellungsverfahren dafür
CN101505736A (zh) 2006-08-25 2009-08-12 贝林格尔.英格海姆国际有限公司 控制释放系统及其制造方法
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
US7998971B2 (en) * 2006-09-08 2011-08-16 Braincells Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
US20080103165A1 (en) * 2006-09-19 2008-05-01 Braincells, Inc. Ppar mediated modulation of neurogenesis
WO2008073928A1 (en) 2006-12-12 2008-06-19 Gilead Colorado, Inc. Composition for treating a pulmonary hypertension
WO2008095136A2 (en) 2007-01-31 2008-08-07 Henkin Robert I Methods for detection of biological substances
BRPI0807281A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Reduzindo os efeitos colaterais de tramadol
BRPI0807282A2 (pt) * 2007-02-12 2014-04-29 Dmi Biosciences Inc Tratamento de ejaculação precoce e disfunção erétil co-mórbidas
WO2008103470A2 (en) * 2007-02-21 2008-08-28 Trustees Of Columbia University In The City Of New York Oncogenic-ras-signal dependent lethal compounds
RU2456989C2 (ru) * 2007-04-25 2012-07-27 Тева Фармасьютикал Индастриес Лтд. Твердые лекарственные формы, содержащие тадалафил
FR2916200A1 (fr) * 2007-05-18 2008-11-21 Fourtillan Snc Nouveaux derives des 1,2,3,4,6,7,12,12a-octahydro pyrazino[1',2':1,6]pyrido[3,4-b]indoles, leur preparation et leur utilisation en therapeutique
DE102007028869A1 (de) 2007-06-22 2008-12-24 Ratiopharm Gmbh Verfahren zur Herstellung eines Arzneimittels enthaltend Tadalafil
US8445698B2 (en) * 2007-06-29 2013-05-21 Ranbaxy Laboratories Limited Process for the preparation of an intermediate of tadalafil
EP2033962A1 (de) * 2007-08-22 2009-03-11 4Sc Ag Tetrazyclische Indolopyridinderivate als EG5-Hemmer
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen
US20090181975A1 (en) * 2008-01-15 2009-07-16 Forest Laboratories Holdings Limited Nebivolol in the treatment of sexual dysfunction
ITMI20080285A1 (it) * 2008-02-22 2009-08-23 Endura Spa Procedimento per la preparazione di esteri di acidi tetraidro-1h-betacarbolin-3-carbossilici
EP2107059A1 (de) * 2008-03-31 2009-10-07 LEK Pharmaceuticals D.D. Umwandlung von Tryptophan in ß-Carbolinderivate
PL385356A1 (pl) 2008-06-03 2009-12-07 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania tadalafilu
US8580801B2 (en) 2008-07-23 2013-11-12 Robert I. Henkin Phosphodiesterase inhibitor treatment
EP2181997A1 (de) 2008-10-30 2010-05-05 Chemo Ibérica, S.A. Verfahren zur Herstellung von Tadalafil
DE102008063992A1 (de) 2008-12-19 2010-09-02 Lerner, Zinoviy, Dipl.-Ing. Neue aliphatisch substituierte Pyrazolopyridine und ihre Verwendung
JP2012513464A (ja) 2008-12-23 2012-06-14 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク ホスホジエステラーゼ阻害剤及びその使用
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
US8586587B2 (en) 2009-02-26 2013-11-19 Thar Pharmaceuticals, Inc. Crystalline molecular complex of tadalafil and methylparaben
GB0903493D0 (en) 2009-02-27 2009-04-08 Vantia Ltd New compounds
DE102009033396A1 (de) 2009-07-16 2011-01-20 Ratiopharm Gmbh Wässrige Lösung und gelatinierte Zusammensetzung umfassend einen Phosphodiesterase-5-Inhibitor sowie diesbezügliche Verfahren und Verwendung
UY33041A (es) 2009-11-27 2011-06-30 Bayer Schering Pharma Aktienegesellschaft Procedimiento para la preparaciòn de {4,6-diamino-2-[1-(2-fluorobencil)-1h-pirazolo[3,4-b]piridin-3-il]pirimidin-5-il}carbamato de metilo y su purificaciòn para el uso como principio activo farmacèutico
US20110136815A1 (en) 2009-12-08 2011-06-09 Horst Zerbe Solid oral film dosage forms and methods for making same
US10610528B2 (en) 2009-12-08 2020-04-07 Intelgenx Corp. Solid oral film dosage forms and methods for making same
WO2011126250A2 (ko) 2010-04-05 2011-10-13 에스케이케미칼 주식회사 Pde5 억제제를 함유하는 피부 주름 개선용 조성물
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
US20120269898A1 (en) 2010-10-15 2012-10-25 Luiz Belardinelli Compositions and methods of treating pulmonary hypertension
WO2012107092A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107541A1 (en) 2011-02-10 2012-08-16 Synthon Bv Pharmaceutical composition comprising tadalafil and a cyclodextrin
WO2012107090A1 (en) 2011-02-10 2012-08-16 Synthon Bv Granulated composition comprising tadalafil and a disintegrant
US8829023B2 (en) 2011-02-10 2014-09-09 Interquim, S.A. Process for obtaining compounds derived from tetrahydro-β-carboline
US20120123124A1 (en) * 2011-04-22 2012-05-17 Drug Process Licensing Associates, LLC Manufacturing process for Tadalafil from racemic or L-tryptophan
CN102180876B (zh) * 2011-05-28 2016-05-18 浙江华海药业股份有限公司 一种他达那非晶型i的制备方法
EP2535049A1 (de) 2011-06-17 2012-12-19 Proyecto de Biomedicina Cima, S.L. Tadalafil zur Behandlung von Demenz
CN102367253B (zh) * 2011-09-20 2016-04-06 浙江华海药业股份有限公司 一种制备他达拉非晶型a的方法
US9402877B2 (en) 2011-11-04 2016-08-02 Xion Pharmaceuticals Corporation Methods and compositions for oral administration of melanocortin receptor agonist compounds
US20150119399A1 (en) 2012-01-10 2015-04-30 President And Fellows Of Harvard College Beta-cell replication promoting compounds and methods of their use
WO2013109738A1 (en) 2012-01-17 2013-07-25 The Trustees Of Columbia University In The City Of New York Novel phosphodiesterase inhibitors and uses thereof
WO2013109225A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Pharmaceutical tablet formulations comprising ceftibuten
WO2013109223A1 (en) 2012-01-18 2013-07-25 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
WO2014092661A1 (en) 2012-01-18 2014-06-19 Mahmut Bilgic Particulate formulations of tadalafil in effervescent form
EP2821066B1 (de) 2012-02-28 2018-04-25 Seoul Pharma. Co. Ltd. Schnell auflösender film mit hohem gehalt und maskierung des bitteren geschmacks mit sildenafil als wirkstoff
US20150297601A1 (en) 2012-10-05 2015-10-22 Robert I. Henkin Phosphodiesterase inhibitor treatment
JP6120985B2 (ja) 2012-12-04 2017-04-26 アリビオ， インコーポレーテッド ホスホジエステラーゼタイプ５活性阻害剤を含む神経細胞のアポトーシス抑制用組成物
KR101953735B1 (ko) 2012-12-14 2019-03-04 한미약품 주식회사 포스포다이에스터라제-5 억제제를 포함하는 츄정
WO2014100733A1 (en) 2012-12-21 2014-06-26 Mayo Foundation For Medical Education And Research Methods and materials for treating calcific aortic valve stenosis
SG11201506211RA (en) 2013-02-21 2015-09-29 Adverio Pharma Gmbh Forms of methyl {4,6-diamino-2-[1-(2-fluorobenzyl)-1h-pyrazolo[3,4-b]pyridino-3-yl]pyrimidino-5-yl}methyl carbamate
CN103232451A (zh) * 2013-05-14 2013-08-07 张家港威胜生物医药有限公司 一种他达那非的简易制备工艺
ES2776353T3 (es) 2013-07-17 2020-07-30 Univ Columbia Inhibidores de la fosfodiesterasa novedosos y usos de los mismos
US20160317542A1 (en) 2013-12-09 2016-11-03 Respira Therapeutics, Inc. Pde5 inhibitor powder formulations and methods relating thereto
EP3108245B1 (de) 2014-02-18 2020-07-22 Robert I. Henkin Verfahren und zusammensetzungen zur diagnose und behandlung des verlustes und/oder der verzerrten wahrnehmung von geschmack oder geruch
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
EP3157520B1 (de) 2014-06-23 2019-09-04 Celgene Corporation Apremilast zur behandlung einer lebererkrankung oder leberfunktionsanomalie
EP2962684A1 (de) 2014-06-30 2016-01-06 Sanovel Ilac Sanayi ve Ticaret A.S. Im mund zerfallende formulierungen von tadalafil
ES2784251T3 (es) 2014-06-30 2020-09-23 Montero Gida Sanayi Ve Ticaret As Formulaciones de disgregación por vía oral de tadalafilo
CN104086546B (zh) * 2014-07-14 2016-08-17 福建广生堂药业股份有限公司 他达拉非的药用酸盐及其制备方法
EP3172207B1 (de) 2014-07-23 2019-03-06 KRKA, d.d., Novo mesto Verfahren zur herstellung des cgmp-phosphodiesterasehemmers und orale pharmazeutische formulierung mit tadalafil-co-präzipitaten
KR101645652B1 (ko) 2014-11-03 2016-08-08 (주)퓨젠바이오농업회사법인 세리포리아 락세라타에 의해 생산되는 세포외다당체를 유효성분으로 함유하는 성기능개선용 조성물
JP6595011B2 (ja) * 2015-06-26 2019-10-23 重▲慶▼迪康▲爾▼▲楽▼制▲薬▼有限公司 新規ホスホジエステラーゼ５阻害剤とその使用
CN105541840B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 关键中间体及其合成方法和在制备他达拉非方面的应用
CN105541835B (zh) * 2015-12-31 2017-12-05 湖南千金湘江药业股份有限公司 顺式四氢咔啉中间体及其合成方法和在制备他达拉非方面的应用
AU2017378409A1 (en) 2016-12-14 2019-07-04 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CN106977516B (zh) * 2017-03-02 2019-06-18 山东裕欣药业有限公司 一种他达拉非的制备方法
RU2692764C1 (ru) 2019-04-26 2019-06-27 Общество с ограниченной ответственностью "Балтфарма" Способ получения тадалафила
CN111995658B (zh) * 2019-05-27 2022-08-02 首都医科大学 Ldv修饰的五环哌嗪二酮及其制备和应用
MX2021015425A (es) 2019-07-15 2022-02-21 Biolab Sanus Farmaceutica Ltda Estereoisomeros del compuesto 3-(benzo[d][1,3]dioxol-5-il)-7-(1-hi droxipropano-2-il)-1-(1h-indol-3-il)-6,7-dihidro-3h-oxazol[3,4-a] pirazina-5,8-diona y su uso como antitumoral y inhibidor de la enzima fosfodiesterasa.
CN110606847A (zh) * 2019-07-30 2019-12-24 中国医药集团总公司四川抗菌素工业研究所 一种他达拉非顺式中间体的制备方法及其应用
WO2021245192A1 (en) 2020-06-04 2021-12-09 Topadur Pharma Ag Novel dual mode of action soluble guanylate cyclase activators and phosphodiesterase inhibitors and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3644384A (en) * 1969-06-09 1972-02-22 Sterling Drug Inc Certain 2-(alpha-haloacetyl) - 1 2 3 4-tetrahydro - 9h - pyrido(3 4-b)indole-3-carboxylates and derivatives
US3717638A (en) * 1971-03-11 1973-02-20 Sterling Drug Inc 1,2,3,4,6,7,12,12A-OCTAHYDRO-2-PHENYLPYRAZINO[2',1':6,1]PYRIDO[3,4-b]INDOLES AND INTERMEDIATES THEREFOR
US3917599A (en) * 1973-03-30 1975-11-04 Council Scient Ind Res 2-Substituted-1,2,3,4,6,7,12,12A-octahydropyrazino(2{40 ,1{40 :6,1)pyrido(3,4-B)indoles
GB1454171A (en) * 1973-10-19 1976-10-27 Council Scient Ind Res Tetracyclic compounds
US4273773A (en) * 1979-09-24 1981-06-16 American Home Products Corporation Antihypertensive tricyclic isoindole derivatives
EP0357122A3 (de) * 1988-08-29 1991-10-23 Duphar International Research B.V Verwendung von Beta-Carbolinen und deren bio-isosterischen Benzofuran- und Benzothiophenanalogen zur Herstellung eines Arzneimittels mit cytostatischer Wirkung
DE3830096A1 (de) * 1988-09-03 1990-03-15 Hoechst Ag Piperazindione mit psychotroper wirkung
GB9514465D0 (en) * 1995-07-14 1995-09-13 Glaxo Lab Sa Chemical compounds
US6046199A (en) * 1998-01-14 2000-04-04 Cell Pathways, Inc. Method of inhibiting neoplastic cells with tetracyclic pyrido[3,4-B]indole derivatives
US6225315B1 (en) * 1998-11-30 2001-05-01 Pfizer Inc Method of treating nitrate-induced tolerance

Also Published As

Publication number Publication date
FI113176B (fi) 2004-03-15
JP4347125B2 (ja) 2009-10-21
SK94096A3 (en) 1997-04-09
LU91017I2 (fr) 2003-05-26
CN1143963A (zh) 1997-02-26
MY114663A (en) 2002-12-31
TW378210B (en) 2000-01-01
HRP950023A2 (en) 1998-04-30
HK1013286A1 (en) 1999-08-20
NL300124I2 (nl) 2003-11-03
FI962927A (fi) 1996-07-19
KR100357411B1 (ko) 2003-02-05
PL179744B1 (pl) 2000-10-31
US20020119976A1 (en) 2002-08-29
CA2181377C (en) 2002-05-28
US6127542A (en) 2000-10-03
HRP950023B1 (en) 2000-10-31
JPH09508113A (ja) 1997-08-19
AU689205B2 (en) 1998-03-26
TNSN95004A1 (fr) 1996-02-06
IS4252A (is) 1995-07-22
UY23893A1 (es) 1995-07-11
FI962927A0 (fi) 1996-07-19
NO306465B1 (no) 1999-11-08
JP2004217674A (ja) 2004-08-05
RO117794B1 (ro) 2002-07-30
GB9401090D0 (en) 1994-03-16
US5859006A (en) 1999-01-12
MX9602904A (es) 1997-12-31
NO963015L (no) 1996-09-09
AP9500712A0 (en) 1995-01-31
SG49184A1 (en) 1998-05-18
RU2142463C1 (ru) 1999-12-10
NO2003002I2 (no) 2005-03-21
NO963015D0 (no) 1996-07-19
NO2003002I1 (no) 2003-01-22
CA2181377A1 (en) 1995-07-27
DE10399006I1 (de) 2003-07-31
IN183942B (de) 2000-05-20
EG25852A (en) 2012-09-10
SV1995000002A (es) 1995-10-04
SI0740668T1 (en) 1999-02-28
MA23433A1 (fr) 1995-10-01
DE69503753D1 (de) 1998-09-03
CZ286566B6 (cs) 2000-05-17
US6784179B2 (en) 2004-08-31
AU707055B2 (en) 1999-07-01
SK280879B6 (sk) 2000-08-14
AU7391298A (en) 1998-08-20
BG62733B1 (bg) 2000-06-30
JP2009102386A (ja) 2009-05-14
AU1574895A (en) 1995-08-08
IS1888B (is) 2003-09-01
PE49495A1 (es) 1996-01-10
EE03231B1 (et) 1999-10-15
EP0740668A1 (de) 1996-11-06
ZA95424B (en) 1995-09-27
IL112384A (en) 1998-08-16
WO1995019978A1 (en) 1995-07-27
JP3808095B2 (ja) 2006-08-09
US6369059B1 (en) 2002-04-09
AP556A (en) 1996-11-07
CO4340684A1 (es) 1996-07-30
DK0740668T3 (da) 1999-05-03
US6025494A (en) 2000-02-15
IL112384A0 (en) 1995-03-30
CN1070492C (zh) 2001-09-05
SA95150475B1 (ar) 2005-07-31
CN1045777C (zh) 1999-10-20
HUT74943A (en) 1997-03-28
ES2122543T3 (es) 1998-12-16
ATE169018T1 (de) 1998-08-15
NL300124I1 (nl) 2003-07-01
BG100727A (bg) 1997-02-28
CN1224720A (zh) 1999-08-04
NZ279199A (en) 1998-01-26
OA10584A (en) 2002-08-26
LV11690B (en) 1997-06-20
HU9601982D0 (en) 1996-09-30
BR9506559C8 (pt) 2020-07-07
DE10399006I2 (de) 2004-05-06
HU222494B1 (hu) 2003-07-28
PL315559A1 (en) 1996-11-12
CZ211696A3 (en) 1997-06-11
BR9506559A (pt) 1997-10-28
LV11690A (lv) 1997-02-20
EP0740668B1 (de) 1998-07-29

Similar Documents

Publication Publication Date Title
DE69503753D1 (de) Tetracyclische derivate, verfahren zu ihrer herstellung und ihre verwendung
DE60033028D1 (de) 5-pyridyl-1,3-azol-derivate, verfahren zu ihrer herstellung und ihre verwendung
ATE294785T1 (de) 2-aminothiazolederivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
ATE206131T1 (de) Phosphonomonoesternnukleinsäuren, verfahren zu ihrer herstellung und ihre verwendung
DE69726593D1 (de) Benzoheterocyclische distamycinderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor- und antivirale mittel
ATE234842T1 (de) Epithilonderivate, verfahren zu deren herstellung und deren verwendung
DE69706690D1 (de) Acryloyl-substituierte distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor- und antivirale mittel
ATA198791A (de) Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
DE69801795T2 (de) Indolyl-pyrrolylidenmethylpyrrol-derivate und verfahren zu ihrer herstellung
DE69908371D1 (de) Thioethergruppen enthaltende distamycin-derivate, verfahren zu ihrer herstellung und ihre verwendung als antitumormittel
DE69523571D1 (de) Pyridylimidazol-derivate und verfahren zu ihrer herstellung
DE59610666D1 (de) Mehrlagenfolie, verfahren zu ihrer herstellung und ihre verwendung
AT399880B (de) Neue thienothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung
DE69518647T2 (de) Pyridyl-imidazol-derivate und verfahren zu ihrer herstellung
ATE200080T1 (de) Benzoxazindionderivate, verfahren zu ihrer herstellung und ihre verwendung
DE59608892D1 (de) Iminooxyphenylessigsäurederivate, verfahren und zwischenprodukte zu ihrer herstellung und ihre verwendung
DE59704380D1 (de) Neue synthetische catecholderivate, verfahren zu ihrer herstellung und ihre verwendung
DE69527445D1 (de) Aminooligosaccharid-derivate und verfahren zu ihrer herstellung
DE59707510D1 (de) Saugfähige einlagen, verfahren zu ihrer herstellung und ihre verwendung
DE69528586D1 (de) Imidazolderivate und verfahren zu ihrer herstellung
DE59700950D1 (de) 5-Z-Octenylester, Verfahren zu ihrer Herstellung und ihre Verwendung
DE59905337D1 (de) Steroidhaltiges pflaster, verfahren zu seiner herstellung und verwendung
DE69932578D1 (de) Trifluoro-methylthiomethyl-benzolderivate und verfahren zu ihrer herstellung
DE69711689T2 (de) Erythromycin-derivate, verfahren zu ihrer herstellung und ihrer verwendung
DE59706268D1 (de) Steroidester, verfahren zu ihrer herstellung und ihre pharmazeutische verwendung

Legal Events

Date Code Title Description
R431 Request for term correction

Free format text: PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112

Spc suppl protection certif: 10399006

Filing date: 20030303

Expiry date: 20150120

Extension date: 20171114

R432 Decision on term correction now final

Free format text: PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112

Spc suppl protection certif: 10399006

Filing date: 20030303

Expiry date: 20150120

Extension date: 20171114

R071 Expiry of right

Free format text: PRODUCT NAME: TADALAFIL; REGISTRATION NO/DATE: EU/1/02/237/001-004 20021112

Spc suppl protection certif: 10399006

Filing date: 20030303

Expiry date: 20150120

Extension date: 20171114